Comparison of PFS and OS between patients treated with blinatumomab maintenance and no posttransplant maintenance (matched-case cohort). At 1 year, the rates of PFS for the blinatumomab vs the control group were 71% vs 68%, P = .44 (A), and the rates for OS for the blinatumomab vs the control group were 85% vs 76%, P = .23 (B).